Therefore, current guidelines vary in their recommendations on whether CHE warrants pharmacologic treatment, and consensus is lacking regarding the timing of initiation, treatment duration, and discontinuation criteria
These effects stabilize blood glucose levels, reducing the metabolic drive for fat storage that occurs with insulin resistance and hyperglycemia
[1] [2] Para el manejo de peso, est indicada en adultos con un IMC 30 kg/m o 27 kg/m con al menos una comorbilidad relacionada con el peso, y en adolescentes de 12 aos o ms con obesidad, siempre como complemento a una dieta reducida en caloras y mayor actividad fsica
Conclusion The latest trials from 2025 confirm that cardiovascular outcomes in diabetes are as important as glycemic control
BPC-157 for gut health support during GLP-1 therapy
In drug-device projects within the cardiometabolic area, the demand is often high